Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Institutions of which they are part Head of group Biomedical Research in Cancer Stem Cells Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Matilde Lleonart Pajarin LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Biomedical Research in Cancer Stem Cells Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Projects RTICC - Red Temática de Investigación cooperativa de cáncer IP: Santiago Ramon y Cajal Agüeras Collaborators: Matilde Lleonart Pajarin, Cleofé Romagosa Pérez-Portabell, Teresa Moline Marimon, Carmela Iglesias i Felip, Josep Castellví Vives, Elena Antima Martinez Saez, Javier Hernandez Losa, Trond Aasen Funding agency: Instituto de Salud Carlos III Funding: 631500.61 Reference: RD06/0020/0104 Duration: 02/01/2007 - 31/12/2014 Estudi i identificació de nous gens de senescència i factors pivot o comodí en senyalització cel·lular, l'angiogènesi i la invasivitat en carcinomes de còlon i mama. Una correlació clinicopatològica IP: Santiago Ramon y Cajal Agüeras Collaborators: Matilde Lleonart Pajarin, Manuel Armengol Carrasco, Eloy Espín Basany, Javier Hernandez Losa Funding agency: Fundació La Marató de TV3 Funding: 245453 Reference: TV3/052710 Duration: 01/01/2006 - 31/12/2008 Estudio e identificación de nuevos genes de senescencia y factores pivotales o comodines en señalización celular, angiogénesis e invasividad en carcinomas humanos: correlación clínico-patológica IP: Santiago Ramon y Cajal Agüeras Collaborators: Matilde Lleonart Pajarin, Angel García Jiménez, Josep Castellví Vives, Javier Hernandez Losa Funding agency: Instituto de Salud Carlos III Funding: 102340 Reference: PI050818 Duration: 01/01/2006 - 31/12/2009 Imiten les cèl·lules canceroses l'estratègia de les cèl·lules mare embrionàries per ser immortals? IP: Matilde Lleonart Pajarin Collaborators: Santiago Ramon y Cajal Agüeras Funding agency: Fundació La Marató de TV3 Funding: 221100 Reference: TV3/052130 Duration: 01/01/2006 - 31/12/2009 Pagination First page « Previous page ‹ … Page 4 Page 5 Page 6 Current page 7 Page 8 Next page › Last page »
